• Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update
• Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023
• The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations
• Lexaria looks to build on the momentum gathered so far, and its management is optimistic that it will achieve its objectives for the 2023 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its mid-year update, marking significant strides both in its research and in creating value for its shareholders. In a report by Zacks Small Cap Research, the company’s critical milestones for the current calendar year were highlighted, from recent publications to awarded patents and capital raised thus far.

Of note was Lexaria’s most ambitious clinical study yet, HYPER-H21-4, a clinical study exploring the potential of the company’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension. Enrollments for the study kicked off in April 2022, with dosing beginning ahead of schedule and completed on July 27th (https://ibn.fm/xxzAj). With the success of this study so far, Lexaria is on track to file an Investigational New Drug application with the U.S. Food and Drug Administration, for DehydraTECH-processed CBD later this year, in addition to tapping into the hypertension treatment market that is estimated to hit $39.5 billion in value by 2030 (https://ibn.fm/UVij4).

Lexaria has also made significant strides in growing its patent portfolio, with its 28th patent worldwide being awarded in late December 2022. Two additional announcements were made in April and June highlighting several global grants, in addition to six patents awarded across Australia, Japan, the United States, and Canada so far in 2023. This goes a long way in strengthening the Lexaria brand, as evidenced by the $2 million capital raise on May 8th.

This capital raise in a public offering saw 2,106,000 units sold at $0.95 per unit, consisting of one share of stock and a warrant with an exercise price of $0.95 per share, offering a five-year term. It showed shareholders’ confidence in the company and its efforts to grow its operations and fulfill its mandate. It was also a show of the company’s growth and future ambitions.

Lexaria also noted significant progress on its nicotine operations, particularly given its receipt of Independent Review Board (“IRB”) approval for its human nicotine study designated NIC-H22-1. Similar progress was made on its Estradiol hormone study, with the recently-concluded animal study HOR-A22-1 demonstrating successful delivery of estradiol and its metabolite estrone using DehydraTECH. These, and more efforts from Lexaria, were recognized in research circles, with eight research paper publications playing a massive role in it.

In a June 22nd press release, Lexaria acknowledged its most recent publication in the International Journal of Molecular Sciences, titled Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study. The publication noted that CBD concentrations were higher in women than men and correlated with the proportion of adipose tissue. The difference in sexes, it noted, was attributed to higher levels of fat tissue in women than men.

Lexaria looks to build on its momentum so far and achieve its objectives for the 2023 calendar year. Its management is optimistic that these goals, and more, will be achieved in the year and that the company will continue to create value for its shareholders while at it.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• First Tellurium in June 2023 successfully uplisted from the OTC Pink Market to the OTCQB Venture Market
• First Tellurium has contracted for IP geophysics on its Deer Horn Project during summer 2023 to develop targets for a drilling program
• The company has engaged consultants to stake additional claims around its Klondike gold-tellurium project in Colorado
• Key applications for tellurium include high efficiency cadmium telluride solar panels, next-gen lithium-ion batteries, semiconductors, thermoelectric devices, phase-change memory chips and low-energy desalination
• The company plans to investigate and acquire other tellurium projects in North America

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

The company is headquartered in Vancouver, British Columbia.

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has began permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (“IP”) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (“CGS”), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (“IEA”) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc. With limited resources in a difficult market environment, he raised more than $30 million and advanced its Quebec iron ore property to a viable project. Quinto later sold for $175 million. From 2012 to 2018, he was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• Legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing – some within 24 months or less for developing and deploying demos, proofs of concepts, and pilots
• Global government spending on quantum application development is expected to reach $36 billion during 2023
• D-Wave offers quantum solutions to help government and public sector develop applications that can solve important optimization problems

Recent legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing applications to solve complex public sector optimization problems, which could include electrical grid resilience, optimization of ports, global supply chain issues, emergency management and response, infrastructure, and telecommunication networks.  D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, has the technology necessary to develop these applications today for the optimization problems faced by the government and the public sector.

“The country is at a unique inflection point for U.S. quantum policy. To date, the U.S. National Quantum Strategy has not prioritized application development, but legislation before Congress has shifted that mindset,” said Dr. Alan Baratz, CEO of D-Wave (https://ibn.fm/pPYnJ). “D-Wave stands ready to collaborate with the U.S. government to build near-term quantum applications to help meet current and future public sector needs.”

The National Defense Authorization Act (“NDAA”) and the FY24 Energy and Water Appropriations bill, currently in the House of Representatives, advance policies that include developing near-term quantum applications. These represent an important shift in the government’s mindset about quantum, which had previously been focused on longer-term gate-model quantum solutions. The NDAA and Appropriation bills explicitly call for policies that include all viable quantum computing systems – including quantum annealing, gate-model, and quantum-hybrid technologies (quantum plus classical computing applications). The current legislation also includes an aggressive timeframe of 24 months or less for developing and deploying demos, proofs of concepts, and pilots.

Three other pieces of legislation regarding quantum are currently at various stages of the approval process. The Quantum Sandbox bill, presented in April 2023, calls for quantum and quantum-hybrid development and is proposed to amend the National Quantum Initiative Act to establish a public-private partnership for near-term application development and acceleration (https://ibn.fm/rV4iq). Additionally, the Wildfire Tech DEMO Act seeks quantum technology for wildfire response (https://ibn.fm/B2jCI), and the Quantum Practice Act calls for quantum technology use for modeling and simulations (https://ibn.fm/FNoQP).

All of the legislation supporting the use of quantum technology comes at a time when global government spending on quantum application development is increasing and is expected to reach $36 billion by the end of the year (https://ibn.fm/o7Rx2). Originally enacted in December 2018, the National Quantum Initiative Act is scheduled for reauthorization this year.

D-Wave, the world’s first commercial supplier of quantum computing solutions, is already providing solutions to its broad portfolio of commercial and government customers in areas such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, and financial modeling, using the company’s quantum annealing technology. Companies, including Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin, are contributing to the company’s use cases through its collection of client success stories (https://ibn.fm/6HH95).

D-Wave stands ready to execute on the government’s shift to build near-term quantum applications with technology uniquely suited for solving the problems currently faced by the government and public sector’s optimization problems.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Data is one of the most valuable and critical assets for today’s businesses, but with cyber-attacks on the rise it can quickly become one of their greatest liabilities
• Alarming statistics reveal that the number of security executives reporting security incidents in software-as-a-service environments surged from 43% to 55% over the past two years, with data leakage as the most common type of security incident, followed by malicious apps, data breaches, and ransomware
• Amid the current climate of ongoing data breach news, Data443 Risk Mitigation aims to cement its position as the provider of “All Things Data Security” by continuing to upgrade its product offering, securing new clients, and long-term customer renewals

“We are proud to be entrusted with our customer’s data, especially given the growing legal and regulatory risks within this environment of continuous data breaches,” said Jason Remillard, CEO and founder of Data443 Risk Mitigation (OTC: ATDS). “Our strength in Enhanced File Transfer/Managed File Transfer (EFT/MFT) with some of the world’s largest fintech enterprises positions Data443 to continue growing relationships in fintech and beyond as more enterprises leverage the public cloud for scale, cost savings, and disaster recovery. The company announced its latest product update—the addition of antivirus and ransomware protection to its EFT/MFT solution (https://ibn.fm/0gH0j).

As a data security and privacy software company, Data443 Risk Mitigation prides itself on securely processing thousands of sensitive data files per hour for its clients across the globe. The role of computer data continues to grow exponentially, enabling everyone – individuals, businesses, governments, schools, hospitals, and everything else in modern society to be more efficient. Entire businesses and sectors have launched to service the needs of processing and securing data. But in today’s digital business environment, data is also a massive target for cybercriminals. In the past, thieves used to break into bank vaults – now, they are attacking the cloud from anywhere in the world with an internet connection. The cloud has become the new target where the gold bullion of the new age – our data – is stored (https://ibn.fm/uL7yq).

A recent report shows that over 55% of security executives reported a security incident in their software-as-a-service environment over the last two years, marking a 12% surge from the previous year. The study, which surveyed 1,130 IT leaders, demonstrates that data leakage (or the unauthorized transmission of data from an organization to any external source) is the most common type of security incident (58%), followed by malicious apps (47%), data breaches (41%) and ransomware (40%).

Alarming statistics reveal another worrisome trend. More than half of respondents (58%) reported that their current SaaS security solutions cover only 50% or less of their SaaS applications, turning the spotlight on the growing need for robust security measures and increased awareness of the vulnerabilities the businesses open themselves to with the expanding SaaS landscape (https://ibn.fm/jvmJD).

As a data security and privacy software company, Data443 Risk Mitigation aims to tackle these challenges head-on. The company recently announced the enhancement of its Data Placement Manager (“DPM”), an Enhanced File Transfer/Managed File Transfer (EFT/MFT) solution, with antivirus and ransomware protection additions powered by the company’s Ransomware Recovery Manager (“RRM”), which was named “Best for Inexpensive Protection” and “Best for Kiosks” by PC Mag. In a bid to enhance its data security and protection capabilities and cyber threat intelligence (“CTI”) services, the company has recently closed a definitive agreement to acquire select assets from Cyren Ltd., which includes Cyren’s proprietary technology and intellectual property related to threat intelligence, URL categorization, and email security.

The company appears to be on a winning streak amid a recent surge of customer renewals and additional contract wins following the recent influx of fintech clients committing to the company’s EFT/MFT solution. With clients experiencing as much as 99.999% uptime, equivalent to an average of fewer than six minutes of downtime per year, Data443 Risk Mitigation appears committed to achieving its mission to become the go-to provider for “All Things Data Security.”

Data443 Risk Mitigation, Inc. (ATDS) Investor Relations
Matthew Abenante
ir@data443.com 
919-858-6542

For more information, visit the company’s website at www.Data443.com.

NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

• Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial
• The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year
• The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported preliminary evidence of efficacy in the phase 1 portion of the study.

“We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. These data supported the Safety Review Committee’s approval to advance to the Phase 2 expansion portion of the clinical trial which we expect to begin in the third quarter,” said Mark Berger, MD, Chief Medical Officer at Genprex (https://ibn.fm/miTxk).

The Phase 1 clinical data were added to by the recent release of a new patient video featuring a non-small cell lung cancer (“NSCLC”) patient from the Phase 1 portion of the study. The patient highlighted in the video achieved a Partial Response and experienced extended Progression Free Survival (“PFS”). She described her positive experience taking REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year.

The patient’s positive experience has been described as encouraging, mainly because she could continue working full-time while participating in the clinical trial. She only experienced minor side effects from using the lead drug candidate. This is particularly significant since NSCLC is ranked as the most common type of lung cancer, accounting for about 82% of all cases. In addition, the overall survival rate for patients with advanced levels of the condition is alarmingly low, with a five-year survival rate for patients with distant spread standing at 7% (https://ibn.fm/85dk7).

“While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown, and there is no new growth,” noted the NSCLC patient.

“I believe the REQORSA treatment has benefited my life and has increased my time,” she added.

The Safety Review Committee (“SRC”) noted that there were no Dose Limiting Toxcities (“DLTs”) during the Phase 1 trial and approved the advancement of the Acclaim-1 clinical trial to the Phase 2 expansion portion of the trial. The approval is a significant milestone in REQORSA’s development program, and now positions REQORSA as a Phase 2 clinical trial asset.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Reunion Gold is a leading gold explorer in South America’s Guiana Shield, a highly prospective and relatively underexplored region.
• The company’s Oko West Project in Guyana comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion through its local subsidiary.
• Guyana is recognized as a mining-friendly jurisdiction and in 2022 its ranking by the Fraser Institute ranking of mining investment attractiveness increased to 22nd ranked areas in the world and the top country in south America.
• The company’s leadership boasts over 225 years of combined experience in the Guiana Shield.
• On June 13 after only 22 months of drilling at Oko West Kairuni zone, Reunion Gold released a significant and high quality initial mineral resource estimate of 2.47 Moz of indicated Au grading 1.84 g/t and 1.762 Moz of inferred resources grading 2.02 g/t
• The company’s strategy is to advance Oko west using a dual track approach to moving the project forward: 1) Advance development of the Kairuni zone forward rapidly by completing a PEA, targeted for year end 2) Continuing an aggressive exploration program focused on expanding the maiden resource, which remains open and exploring the two highly prospective targets outside of the Kairuni zone MRE area. These targets include the Takutu zone which represents the 4km of the same geological contact and structure that hosts the Kairuni resource and also the Bryan zone which represents the western portion of the property which displays a combination of gold in soil geochemical anomalies and historic alluvial gold mining operations downstream of the area.

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the company has announced an initial Mineral Resource Estimate (“MRE”) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.

Guyana

Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

For more information, visit the company’s website at www.ReunionGold.com.

NOTE TO INVESTORS: The latest news and updates relating to RGDFF are available in the company’s newsroom at https://ibn.fm/RGDFF

• XESP is a market disruptor offering cutting-edge data analysis and intelligent technology to help companies reach their target markets
• The company’s Digital Engagement Engine(TM) technology platform provides clients with meaningful connections that guide their audiences from awareness to action
• Electronic Servitor Publication Network’s disruptive solution helps clients maintain complete control of their content while dynamically connecting with current and new audiences to drive growth

Electronic Servitor Publication Network (OTCQB: XESP) is a market disruptor focused on connecting companies with target audiences to drive predictable growth. XESP’s managed service provides B2B clients with cutting-edge data analysis and intelligent technology to help them reach and connect with their target markets and audiences. XESP helps companies – and their products and services – connect by digitally engaging audiences with content and dialog that otherwise and ordinarily could only be done through direct contact by sales personnel. Their service provides around-the-clock company-consumer interactions, instead of just momentary and episodic contact, to drive growth.

The company has developed the Digital Engagement Engine(TM), a technology platform specifically designed for digital activation and engagement. It is built on workflows and microservices that automate tasks to help companies connect with people digitally, while reducing costs, enhancing user engagement, and achieving growth targets.

There are several excellent customer relationship management (“CRM”), optimization, and omnichannel content publication tools available to companies.  However, the modern companies with whom XESP has interacted, have found that existing tools and technologies have not provided desired results or growth. The cause is multi-faceted, including a lack of integration and costly management of the tools, but the solution these challenges is embedded in the design the Digital Engagement Engine(TM).

XESP has identified deficiencies in how companies represent themselves through digital channels.  Most companies stick to monologues that present their messages and stories without input from the target audience, whereas the modern approach is a two-way dialogue or “conversation” between the company and its customers.

Through its technology stack, XESP solves these challenges by having all tools working together and then leveraging the Digital Engagement Engine(TM), which uniquely handles content provisioning, to promote meaningful interactions between the clients and their audiences.

“The Digital Engagement Engine(TM) overlays with the tools to ensure that you are having a co-created conversation that is meaningful to the individual user rather than a one-size-fits-all. And that meaningful interaction drives a greater relationship with your audience, greater trust, and, ultimately, greater growth in your organization. Very simply put, it replicates what you do face to face, and if we can do that online, which the digital engagement helps you do, you’re going to produce better results,” explained XESP CEO Peter Hager in a recent interview with Spotlight TV (https://ibn.fm/AcoQq).

“So, there’s no need to go out and not leverage a tool that you already have or purchase a new tool. It’s about getting the people and the tools aligned with the right processes to drive the experience and results that CEOs are demanding,” Hager continued.

XESP’s intelligent tech stack, which utilizes data management, also embraces various public social platforms as vital sources of market intelligence and avenues through which companies interact with their customers “on their terms.” By supporting the various social media platforms, XESP lets end consumers decide how they want to interact with brands and their content and the technology stack makes these interactions more meaningful.

All things considered, the company’s disruptive solution helps clients maintain complete control of their content while dynamically connecting with current and new audiences to drive growth.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Skylar recently announced a collaboration with Amazon Prime Video as the official fragrance of “The Summer I Turned Pretty” series
• To celebrate the partnership, Skylar released three rollerball fragrances featuring “The Summer I Turned Pretty” branding: Salt Air, Boardwalk Delight, and Capri Summer
• Skylar fragrances are cruelty-free, vegan, hypoallergenic, and formulated without any of the 36 known perfume allergens or 1,300+ “questionable” ingredients
• Starco Brands, Inc. is an invention factory that invents or acquires innovative products with behavior-changing technologies and leverages an extensive network of manufacturing, distribution, and media partners
• Other Starco Brands include the Art of Sport premium skincare line co-founded by Kobe Bryant, Whipshots(R) vodka-infused whipped cream featuring Cardi B, Winona Pure(R) theater-style popcorn spray and the Soylent line of nutrient-dense food products

The Skylar division of Starco Brands (OTCQB: STCB) makes clean, hypoallergenic fragrances designed to empower individuals with scents that make them feel safe, beautiful, and confident in their skin. The company recently announced its partnership with Amazon Prime Video as the official fragrance of “The Summer I Turned Pretty” – a coming-of-age series that explores themes of love, relationships, identity, and self-discovery.

In celebration of Skylar’s partnership with Amazon Prime Video, the company released three rollerball fragrances featuring “The Summer I Turned Pretty” branding: Salt Air, Boardwalk Delight, and Capri Summer. Vegan, eco-friendly, and hypoallergenic, each limited-edition rollerball is designed to invoke youthful emotions and memories inspired by the sweet scents of summer.

Skylar was founded in 2017 to address allergic reactions to everyday fragrances. Fragrance allergies are relatively common, affecting over two million Americans with symptoms that include eyelid tearing, skin redness, swelling, burning sensations, headaches, breathing difficulties, sneezing, and nasal congestion.

Formulated without any of the 36 known allergens or 1,300+ “questionable” mainstream perfume ingredients, Skylar’s scents are inspired by the spirit and natural landscapes of California. The entire product line, including full-sized fragrance bottles, rollerballs, candles, and gift sets, is available at the company’s online store, 500+ Sephora locations, and through the Skylar Scent Club, which sends products to 10,000+ subscribers each month.

Since its acquisition by Starco Brands, Inc. in Jan. 2023, Skylar continues to operate as a separate business unit. Other products under the Starco Brands umbrella include Winona Pure(R) theater-style popcorn spray powered by air, the award-winning Soylent line of nutrient-dense food products, the Art of Sport premium skincare line co-founded by Kobe Bryant and Whipshots(R) vodka-infused whipped cream featuring Cardi B.

Starco Brands aims to spark delight in the everyday by inventing or acquiring products with behavior-changing technologies. The company’s revenues skyrocketed in 2022 from $2 million to approximately $67 million through a strategy that identifies gaps in eight core consumer categories and fulfills that demand with novel products that disrupt markets, change behaviors, and exceed consumer expectations.

Based in Santa Monica, California, Starco Brands is led by a management team with decades of experience in consumer goods, M&A, business development, and finance. With a stellar product strategy backed by a solid network of manufacturing, distribution, and media partners, the company is strongly positioned to capture a significant share of every market it enters with its portfolio of innovative, behavior-changing brands.

For more information, visit the company’s website at www.StarcoBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB

• Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer
• This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3
• Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq
• The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023
• Genprex is combining its lead product candidate, REQORSA, with existing lung cancer medications – Tagrisso, Keytruda, and Tecentriq – in an effort to help patients benefit for longer periods of time and allow some patients to benefit who may not have benefited at all

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. Food and Drug Administration (“FDA”) Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment (https://ibn.fm/jIv3I).

The FTD is for the company’s Acclaim-3 patient population, and Genprex expects to initiate its Acclaim-3 clinical trial by enrolling the first patient in the third quarter of 2023. The Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq. Patients in this study will be enrolled after receiving treatment with 3-4 cycles of carboplatin, etoposide, and Tecentriq and achieving a complete response, partial response, or stable disease. They will then receive treatment with REQORSA and Tecentriq as maintenance therapy every 21 days until disease progression.

The company has previously received two other FTDs. In 2020, Genprex announced that the FDA had granted FTD for its REQORSA therapy in combination with AstraZeneca’s (NASDAQ: AZN) Tagrisso(R) in patients with late-stage non-small cell lung cancer (“NSCLC”) whose disease has progressed after treatment with Tagrisso (https://ibn.fm/p5bPW). Later, in 2022, the company received its second FTD for REQORSA in combination with Merck & Co Inc.’s (NYSE: MRK) Keytruda(R) in patients whose disease progressed after treatment with Keytruda(R) (https://ibn.fm/Asm5m).

To get a Fast Track Designation, a drug company must file an application with the FDA and provide all non-clinical and clinical data demonstrating the potential for a drug to benefit patients with a serious or life-threatening disease where there is an unmet need. “Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one,” explains the FDA (https://ibn.fm/nFpR4).

“This is another exciting achievement in our REQORSA drug development program, which further validates REQORSA’s potential not only in NSCLC but also in SCLC. We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC,” commented Rodney Varner, Chairman, President, and CEO of Genprex.

As the leading cause of cancer-related deaths globally, accounting for 1.8 million deaths in 2020 or about 18% of total cancer deaths (https://ibn.fm/TCEDH), lung cancer is an obvious example of a serious condition. (Lung cancer was also the second most common type of cancer in 2020, after female breast cancer, accounting for 2.2 million new cases.) With these numbers in mind, Genprex hopes to leverage its lead product candidate to help patients benefit from Tagrisso, Keytruda, or Tecentriq for a longer period of time and allow some patients to benefit who may not have benefited at all.

REQORSA consists of the TUSC2 tumor suppressor gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. “REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell,” explains Genprex’s website (https://ibn.fm/oWpT5).

According to Varner, data generated so far validates the company’s theory that using REQORSA in combination with these lung cancer therapies can extend the benefits of the drugs (https://ibn.fm/0QD5X). These findings are allowing the company to participate in the burgeoning lung cancer drugs market despite its relatively small size compared to AstraZeneca, Genentech, and Merck & Co, for example. Valued at $18.328 billion in 2018, the global lung cancer therapeutics market is expected to grow at a 13% CAGR reaching a value of $48.726 billion by 2026 (https://ibn.fm/R1u7R).

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Freight Technologies (aka Fr8Tech) has developed a technology solution that uses machine learning and artificial intelligence (“AI”) to help shipping and freighting companies optimize product transports and avoid costly errors
• Fr8Tech recently announced that one of its top clients, multinational insulation manufacturing company K-FLEX de México SA de CV, renewed its contract for using Fr8Tech’s core tech solution, Fr8App
• K-FLEX cited Fr8App’s benefits to the company during the difficult COVID-19 pandemic period and beyond as K-FLEX expanded its operations and approaches $1 billion in annual revenues
• Fr8Tech is continuing to expand its technology frontiers with the establishment of a dedicated AI development department within the company’s infrastructure

Supply chain optimization innovator Freight Technologies (NASDAQ: FRGT), aka Fr8Tech, helped shipping companies to keep commercial freight transportation rolling through the worst of the COVID pandemic, and the company’s dedication to its clients has resulted in a contract renewal with multinational insulation manufacturing company K-FLEX, according to a June 22 announcement.

“Fr8App delivered cross-border capacity during a difficult time for us as we worked first through the COVID-19 pandemic and then through our plant expansion challenges in Mexico and many times under conditions that others in the logistics industry were not willing to accept,” K-FLEX de México SA de CV President Maged Anis stated in the news release (https://ibn.fm/evIS0). “With our newly completed plant expansion, we will have over 100 trucks per week crossing from Mexico to the United States, and Fr8App’s solutions will play a huge role in managing our logistics seamlessly across the U.S.-Mexico border.”

Fr8Tech has assembled a family of brands surrounding its Fr8App flagship technology, which is an AI and machine learning technology that serves as a B2B freight matching platform. By simplifying the complicated process of securing international over-the-road (“OTR”) shipping, Fr8App makes it possible for freighting businesses to avoid costly errors and expand their operations.

Building on its automated strengths, Fr8Tech recently announced that it had appointed Dr. Umberto León-Domínguez to oversee the creation of a dedicated AI development department under the company’s banner to continue expanding the solutions the company can offer freighters.

“The vision of a future where AI fundamentally transforms goods transportation is exhilarating. In particular, the emergence of autonomous trucks and unmanned aerial vehicles holds the promise of increasing delivery efficiency and significantly reducing labor costs,” León-Domínguez stated (https://ibn.fm/AyHRO).

Fr8Tech’s area of operations includes shipping throughout the United States-Mexico-Canada Agreement trade area known as the USMCA (formerly NAFTA). León-Domínguez will be based in the company’s operations center in Monterrey, Mexico.

Fr8App allows users to network with each other to post their loads and the destination within the USMCA, along with the amount and desired price, and then provides matching options based on available cargo space in less-than-full truckloads already scheduled. It also provides tracking functionality for the shipment.

Fr8Tech CEO Javier Selgas noted that K-FLEX “is well on its way to surpassing $1 billion in annual revenue” and is one of Fr8Tech’s top clients, so the renewal is a cause for celebration. “We believe this is just the beginning of many great things to come,” he stated.

For more information, visit the company’s website at www.Fr8Technologies.com, and their its matching platform information site at www.Fr8.app. 

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com